AU2007221503A1 - Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding RPS27L protein - Google Patents

Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding RPS27L protein Download PDF

Info

Publication number
AU2007221503A1
AU2007221503A1 AU2007221503A AU2007221503A AU2007221503A1 AU 2007221503 A1 AU2007221503 A1 AU 2007221503A1 AU 2007221503 A AU2007221503 A AU 2007221503A AU 2007221503 A AU2007221503 A AU 2007221503A AU 2007221503 A1 AU2007221503 A1 AU 2007221503A1
Authority
AU
Australia
Prior art keywords
cell
rps27l
cells
protein
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007221503A
Other languages
English (en)
Inventor
Qiang Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of AU2007221503A1 publication Critical patent/AU2007221503A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007221503A 2006-03-02 2007-03-01 Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding RPS27L protein Abandoned AU2007221503A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77851906P 2006-03-02 2006-03-02
US60/778,519 2006-03-02
PCT/SG2007/000058 WO2007100305A1 (en) 2006-03-02 2007-03-01 Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein

Publications (1)

Publication Number Publication Date
AU2007221503A1 true AU2007221503A1 (en) 2007-09-07

Family

ID=38459335

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007221503A Abandoned AU2007221503A1 (en) 2006-03-02 2007-03-01 Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding RPS27L protein

Country Status (6)

Country Link
US (1) US20090137517A1 (enExample)
EP (1) EP1996206A4 (enExample)
JP (1) JP2009528346A (enExample)
AU (1) AU2007221503A1 (enExample)
TW (1) TW200800236A (enExample)
WO (1) WO2007100305A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710286B1 (pt) 2006-04-26 2019-05-07 Litens Automotive Partnership Isolador unidirecional para tranferir torque entre um meio de acionamento flexível e um dipositivo
JP5436786B2 (ja) * 2008-03-06 2014-03-05 オリンパス株式会社 細胞周期計測方法
US20110023151A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of abc transporters
US20110023149A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in tumor suppression in animals
US20110023154A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Silkworm genome editing with zinc finger nucleases
US20110016543A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genomic editing of genes involved in inflammation
US20110023148A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of addiction-related genes in animals
US20110023141A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved with parkinson's disease
US20110016539A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of neurotransmission-related genes in animals
US20110023158A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Bovine genome editing with zinc finger nucleases
US20110023146A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in secretase-associated disorders
US20110016546A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Porcine genome editing with zinc finger nucleases
US20110023150A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of genes associated with schizophrenia in animals
US20110023140A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Rabbit genome editing with zinc finger nucleases
US20110023144A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in amyotrophyic lateral sclerosis disease
US20110016540A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of genes associated with trinucleotide repeat expansion disorders in animals
US20110023153A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in alzheimer's disease
US20110023143A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of neurodevelopmental genes in animals
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
US20110023147A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of prion disorder-related genes in animals
US20110023145A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in autism spectrum disorders
US20110023156A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Feline genome editing with zinc finger nucleases
US20110023139A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genomic editing of genes involved in cardiovascular disease
US20110030072A1 (en) * 2008-12-04 2011-02-03 Sigma-Aldrich Co. Genome editing of immunodeficiency genes in animals
US20110016541A1 (en) * 2008-12-04 2011-01-20 Sigma-Aldrich Co. Genome editing of sensory-related genes in animals
CA2821547A1 (en) * 2010-12-29 2012-07-05 Sigma-Aldrich Co. Llc Cells having disrupted expression of proteins involved in adme and toxicology processes
EP3564385A4 (en) * 2016-12-27 2020-08-12 Sumitomo Chemical Company, Limited ASSESSMENT AND SELECTION PROCEDURE FOR INDUCED PLURIPOTENT STEM CELLS, AND PROCESS FOR MANUFACTURING INDUCED PLURIPOTENT STEM CELLS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756309A2 (en) * 2004-06-03 2007-02-28 Bayer HealthCare AG Methods for predicting and monitoring response to cancer therapy
WO2006006939A1 (en) * 2004-07-09 2006-01-19 Agency For Science, Technology And Research MODULATION OF GSK-3β AND METHOD OF TREATING PROLIFERATIVE DISORDERS

Also Published As

Publication number Publication date
EP1996206A4 (en) 2010-09-22
JP2009528346A (ja) 2009-08-06
WO2007100305A1 (en) 2007-09-07
EP1996206A1 (en) 2008-12-03
US20090137517A1 (en) 2009-05-28
TW200800236A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
US20090137517A1 (en) Sensitizing a cell to cancer treatment by modulating the activity of a nucleic acid encoding rps27l protein
Li et al. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress
JP5902138B2 (ja) 癌治療と幹細胞調節のための方法
US20110117627A1 (en) Regulation of apoptosis by neural specific splice variants of ig20
EP2937099A1 (en) Apoptosis-inducing agent
CN103561750A (zh) 通过microRNA-155(miR-155)诱导的增变活性使炎症与癌症关联
US20180251763A1 (en) Compositions and Methods for Inducing Senescence in Cancer Cells
JP7646359B2 (ja) ｍｉＲ－１８１阻害剤及びその使用
CN104302767A (zh) 用于减少肺癌肿瘤发生和化学疗法抗性的MiRNA以及相关组合物和方法
Liu et al. Ciz1 promotes tumorigenicity of prostate carcinoma cells
WO2007084954A2 (en) Selective inhibition of ig20 splice variants to treat cancers
EP2182958A1 (en) Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma
US10697020B2 (en) MicroRNA-129 as a biomarker for colorectal cancer
WO2014110163A2 (en) Melk regulation for the treatment of breast cancer
JP2016196486A (ja) 脳腫瘍を治療するための分枝鎖アミノトランスフェラーゼ１（ｂｃａｔ１）の阻害剤
EP2132313B1 (en) Inhibitors of mrp4 for the treatment of vascular disorders
KR101525122B1 (ko) Ｕｂｂ 넉­다운에 의한 암의 예방 또는 치료
KR102143701B1 (ko) nc886 및/또는 PKR 저해제를 포함하는 항암 보조제, 및 암 치료를 위한 약물의 정보 제공 방법
US20230270881A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
AU2022384267A1 (en) Lncrna transcripts in melanomagenesis
AU2008313240A1 (en) RNAi mediated knockdown of NuMA for cancer therapy
WO2011041784A1 (en) Methods for diagnosing and treating cancer
WO2009035804A2 (en) Gene silencing of the brother of the regulator of imprinted sites (boris)
KR20230045386A (ko) miR-4487를 유효성분으로 함유하는 항암제 민감성 증진용 조성물
Randvra Combination SiRNA Targeting Bcl-2 Antagonizes SiRNA Against Thymidylate Synthase (TS) in Human Tumor Cell Lines

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application